Nuclear Imaging

Molecular imaging, also called nuclear imaging, includes positron emission computed tomography (PET) and single photon emission computed tomography (SPECT) imaging. This section includes radiopharmaceuticals and tracers, PET-CT, SPECT-CT, and PET-MRI.

For teleradiology groups, ensuring they have the radiologist capacity and technology in place will be essential to capitalize on the opportunity for robust market growth

Feature | Teleradiology | By Arun Gill

Outpatient Imaging And Teleradiology Changing the Market Dynamic in the US

The healthcare market is witnessing a dynamic shift in how and where patients want to receive care, with the flexibility ...

July 12, 2023

A collaboration to advance development of a fibroblast activation protein (FAP)-targeted PET diagnostic compound for a broad array of epithelial-derived cancers

News | Radiopharmaceuticals and Tracers

First Patient Dosed in Phase I Study Evaluating a Novel FAP-Targeted Radiopharmaceutical for PET Imaging

July 11, 2023 — Ratio Therapeutics Inc. (Ratio), a pharmaceutical company that employs a suite of innovative ...

July 11, 2023

Coronary computed tomography angiography is a cheaper, less-invasive alternative to intravascular ultrasound in pharmaceutical clinical trials

Feature | Cardiac Imaging | By Matthew Jay Budoff, MD, FACC, FAHA

The Benefits of Coronary CTA in Pharmaceutical Clinical Trials

Coronary computed tomography angiography (CCTA) is cheaper, easier to use and its results are easier to understand than ...

July 11, 2023

Sponsored Content

Staging F-18 FDG PET/CT images of adenocarcinoma in the RUL of the lung illustrates the value of Vereos. The primary lesion in the right upper lobe appears in the upper row (PET image is left, CT image is right). A 3 mm synchronous primary or metastatic lesion in the RUL is apparent in the lower row. The precision afforded by Vereos' images provided the basis for the patient to undergo RUL lobectomy instead of thermal ablation of the primary lesion. Images courtesy of Dr. Jay Kikut and UVM

Blog | PET-CT

Digital PET Balances Scan Time and Resolution

Efficiency and effectiveness are inseparable in clinical medicine. Digital PET addresses them both. The key is the ...

October 25, 2018

NorthStar’s high purity non-carrier-added (n.c.a.) Ac-225 to be used in advancing Nucleus’ partners radioligand therapies to treat cancer

News | Molecular Imaging

NorthStar Medical Radioisotopes Announces Supply Agreement with Nucleus RadioPharma for Alpha-emitting Therapeutic Radioisotope Actinium-225 (Ac-225)

July 5, 2023 — NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and ...

July 05, 2023

City of Hope researchers establish foundation to expand SCINTIX therapy using a prostate cancer-specific PET radiotracer

News | Prostate Cancer

RefleXion Highlights Clinical Study Results for Future Prostate Cancer Treatment

July 3, 2023 — RefleXion Medical, Inc., a therapeutic oncology company, today announced that results of a prospective ...

July 03, 2023

The Society of Nuclear Medicine and Molecular Imaging (SNMMI) hosted nearly 8,000 physicians, technologists, pharmacists, laboratory professionals, scientists and others at its 2023 Annual Meeting, themed “Eye on the Patient,” held in Chicago, Illinois.

News | SNMMI

SNMMI Keeps “Eye on the Patient” at 2023 Annual Meeting

June 30, 2023 — The Society of Nuclear Medicine and Molecular Imaging (SNMMI) hosted nearly 8,000 physicians ...

June 30, 2023

Digital detectors with proprietary LSO crystals deliver high-resolution imaging

News | PET-CT

Siemens Healthineers Debuts Biograph Vision.X PET/CT Scanner

June 29, 2023 — At the 2023 Annual Meeting of the Society of Nuclear Medicine & Molecular Imaging (SNMMI), June 24-27 at ...

June 29, 2023

News | SNMMI

Research Showing Genomics- and Image-Guided Subtyping Refines Characterization of Alzheimer’s Disease Presented at SNMMI 2023

June 29, 2023 — Research presented at the 2023 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging ...

June 29, 2023

News | SNMMI

Prostate Cancer Treatment Study at SNMMI 2023 Finds Improved Patient Outcomes with Personalized Dosing

June 29, 2023 — A study presented this week during the 2023 Society of Nuclear Medicine and Molecular Imaging (SNMMI) ...

June 29, 2023

The integration of its advanced AIR technologies with the SIGNA PET/MR AIR system, to enhance diagnostic precision, simplify treatment evaluation, while elevating patient comfort

News | SNMMI

GE HealthCare Advances PET/MR Capabilities with AIR Technologies

June 28, 2023 — GE HealthCare is set to unveil SIGNA PET/MR AIR[i], at the Society of Nuclear Medicine and Molecular ...

June 28, 2023

Molecular imaging with 18F-flubatine PET/MRI has shown that neuroreceptors in the brains of individuals with obesity respond differently to food cues than those in normal-weight individuals, making the neuroreceptors a prime target for obesity treatments and therapy

News | SNMMI

Molecular Imaging Identifies Brain Changes in Response to Food Cues; Offers Insight into Obesity Interventions

June 28, 2023 — Molecular imaging with 18F-flubatine PET/MRI has shown that neuroreceptors in the brains of individuals ...

June 28, 2023

A newly discovered radionuclide-based agent (CB-2PA-NT) has been shown to have high tumor uptake, sustained tumor retention, and high contrast in preclinical models, making it a prime candidate for a novel theranostics approach

News | SNMMI

Novel Theranostic Agent Targets Multiple Cancer Types

June 28, 2023 — A newly discovered radionuclide-based agent (CB-2PA-NT) has been shown to have high tumor uptake ...

June 28, 2023

A novel PET perfusion radiotracer, 18F-flurpiridaz, can diagnose coronary artery disease (CAD) in obese patients with a higher sensitivity and specificity compared to 99Tc-SPECT myocardial perfusion imaging (MPI)

News | SNMMI

Novel Radiotracer Demonstrates High Diagnostic Efficacy for Obese Patients with Coronary Artery Disease

June 28, 2023 — A novel PET perfusion radiotracer, 18F-flurpiridaz, can diagnose coronary artery disease (CAD) in obese ...

June 28, 2023

News | SNMMI

Society of Nuclear Medicine and Molecular Imaging Names Helen Nadel, MD, FRCPC, of Stanford, as President, Announces New Officers at SNMMI 2023 Annual Meeting

June 27, 2023 — Helen Nadel, MD, FRCPC, director of pediatric nuclear medicine at Lucile Packard Children’s Hospital at ...

June 27, 2023

Contrast-enhanced mammography (CEM) is an emerging modality combining digital mammography with the administration of a contrast agent

News | Contrast Media

FDA approves Bayer’s Ultravist (iopromide) Injection for Contrast-enhanced Mammography

June 26, 2023 — Bayer announced that Ultravist (iopromide)-300, -370, its iodine-based contrast agent, has been approved ...

June 26, 2023

Nizar A. Mullani, one of the pioneers of the first positron emission tomography (PET) prototype, has been named as this year’s recipient of the Georg Charles de Hevesy Nuclear Pioneer Award.

News | SNMMI

Nizar A. Mullani Receives SNMMI 2023 Georg Charles de Hevesy Nuclear Pioneer Award

June 26, 2023 — Nizar A. Mullani, one of the pioneers of the first positron emission tomography (PET) prototype, has ...

June 26, 2023

Umar Mahmood, MD, PhD, chief of Nuclear Medicine and Molecular Imaging, director of the Center for Precision Imaging, and associate chair for imaging sciences in the Department of Radiology at Massachusetts General Hospital and professor of radiology at Harvard Medical School in Boston, Massachusetts, has been named as the first recipient of the new Minoshima-Pappas Transformational Leadership Award.

News | SNMMI

Umar Mahmood, MD, PhD, Receives First Annual SNMMI Minoshima-Pappas Transformational Leadership Award

June 26, 2023 — Umar Mahmood, MD, PhD, chief of Nuclear Medicine and Molecular Imaging, director of the Center for ...

June 26, 2023

News | SNMMI

Study on Value of 68Ga-FAPI PET/CT Imaging for Evaluation of Disease Activity in Rheumatoid Arthritis presented during SNMMI 2023

June 26, 2023 — PET imaging with 68Ga-FAPI offers a feasible, reliable, and reproducible method for evaluating disease ...

June 26, 2023

During its 2023 Annual Meeting, the Image of the Year was selected by the Society of Nuclear Medicine and Molecular Imaging (SNMMI), and represents research presented which reports on the ability of a novel theranostic pair to successfully detect metastatic pancreatic cancer and provide a means of selecting appropriate treatments.

News | SNMMI

Image of the Year and Research Announced at SNMMI 2023 on Theranostic Pair for Early Detection and Effective Treatment of Pancreatic Cancer

June 26, 2023 — A first-in-human evaluation of the novel theranostic pair 68Ga-DOTA-5G / 177Lu-DOTA-ABM-5G has confirmed ...

June 26, 2023

A new PET radiotracer that visualizes the enzyme primarily responsible for metabolic cholesterol degradation in the brain has been successfully validated

News | SNMMI

Translational PET Tracer Visualizes Brain Cholesterol Metabolism

June 25, 2023 — A new PET radiotracer that visualizes the enzyme primarily responsible for metabolic cholesterol ...

June 25, 2023